Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers
Emily C. Ayers(University of Virginia), Narendranath Epperla(University of Utah), Debamita Kundu(University of Virginia), Allison Winter(Cleveland Clinic), Mehdi Hamadani(Medical College of Wisconsin), Yazeed Sawalha(Cleveland Clinic), Boyu Hu(University of Utah), Kaitlin Annunzio(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Steven M. Bair(University of Colorado Cancer Center), Scott F. Huntington(Yale Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Ning Dong(Moffitt Cancer Center), Aditi Saha(Moffitt Cancer Center), Ashwath Gurumurthi(Medical University of South Carolina), Daniel J. Landsburg(University of Pennsylvania), Mwanasha H. Merrill(Dana-Farber Cancer Institute), John H. Baird(City Of Hope National Medical Center), Jennifer Santos(University of Colorado Anschutz Medical Campus), Nazila Shafagati(Sidney Kimmel Comprehensive Cancer Center), Ranjana H. Advani(Stanford Medicine), Viktoriya Zelikson(University of Virginia), Fateeha Furqan, Cole Sterling(Sidney Kimmel Comprehensive Cancer Center), Brad S. Kahl(UW Health University Hospital), Hanan Alharthy(University of Maryland, Baltimore), Natalie S. Grover(University of North Carolina at Chapel Hill), Jason T. Romancik(Emory University), Leyla Bojanini(Stanford University), Behzad Amoozgar(Washington University in St. Louis), P. Connor Johnson(Harvard University), David Qualls(Memorial Sloan Kettering Cancer Center), Carrie Ho(University of California, San Francisco), Jennifer L. Crombie(Dana-Farber Cancer Institute), Stephen D. Smith(Seattle Cancer Care Alliance), Jennie Y. Law(University of Maryland, Baltimore), Zachary AK Frosch(Fox Chase Cancer Center), Shuning Li(Beijing Tongren Hospital), Mayur Narkhede(University of Alabama at Birmingham), Pavan Challa(Yale University), Katelin Baird(Emory University)
Cited by 10
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k